Publications by authors named "Angus Dalgleish"

Claim this Profile
E
Expression of EGFRvIII and its co‑expression with wild‑type EGFR, or putative cancer stem cell biomarkers CD44 or EpCAM are associated with poorer prognosis in patients with hepatocellular carcinoma.
Ozlem Sherif, Said A Khelwatty, Izhar Bagwan, Alan M Seddon, Angus Dalgleish

Oncol Rep· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Releasing the restraints of Vγ9Vδ2 T-cells in cancer immunotherapy.
Laura A Ridgley, Jonathan Caron, Angus Dalgleish, Mark Bodman-Smith

Front Immunol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Editorial: Immunotherapy for Prostate Cancer - turning the immunological desert into an oasis of hope.
Christine Galustian, Angus Dalgleish, Mark Bodman-Smith, Sergei Kusmartsev, Prokar Dasgupta

Front Oncol· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of immune modulation and anti-inflammatory agents in the management of prostate cancer: A case report of six patients.
Angus G Dalgleish, Wai M Liu

Oncol Lett· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination of cannabidiol with low‑dose naltrexone increases the anticancer action of chemotherapy and .
Wai M Liu, Nadine K Hall, Harry S Y Liu, Francis L Hood, Angus G Dalgleish

Oncol Rep· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Naltrexone at low doses (LDN) and its relevance to cancer therapy.
Wai M Liu, Angus G Dalgleish

Expert Rev Anticancer Ther· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selection and T-cell antigenicity of synthetic long peptides derived from SARS-CoV-2.
Katarzyna Piadel, Amin Haybatollahi, Angus George Dalgleish, Peter Lawrence Smith

J Gen Virol· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Directing T-Cell Immune Responses for Cancer Vaccination and Immunotherapy.
Peter Lawrence Smith, Katarzyna Piadel, Angus George Dalgleish

Vaccines (Basel)· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The immuno-oncological implications of insulin.
Gustav van Niekerk, Angus G Dalgleish, Fourie Joubert, Annie Joubert, Anna-Mart Engelbrecht

Life Sci· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of carboplatin when administered after dacarbazine failure: Clinical benefit of sequential therapy.
Eve Merry, Maria Marples, Sarah Danson, David Harding, James Denny, Angus G Dalgleish

Mol Clin Oncol· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The efficacy of chemotherapeutic drug combinations may be predicted by concordance of gene response to the single agents.
Andrew M Gravett, Jayne L Dennis, Angus G Dalgleish, John Copier, Wai M Liu

Oncol Lett· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synergistic activity of agents targeting growth factor receptors, CDKs and downstream signaling molecules in a panel of pancreatic cancer cell lines and the identification of antagonistic combinations: Implications for future clinical trials in pancreatic cancer.
Tanzeel Khan, Alan M Seddon, Angus G Dalgleish, Said Khelwatty, Nikolaos Ioannou

Oncol Rep· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The cytotoxic molecule granulysin is capable of inducing either chemotaxis or fugetaxis in dendritic cells depending on maturation: a role for Vδ2 γδ T cells in the modulation of immune response to tumour?
Emma L Sparrow, Daniel W Fowler, Joe Fenn, Jonathan Caron, John Copier, Angus G Dalgleish

Immunology· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mitigating Coronavirus Induced Dysfunctional Immunity for At-Risk Populations in COVID-19: Trained Immunity, BCG and "New Old Friends".
Thomas-Oliver Kleen, Alicia A Galdon, Andrew S MacDonald, Angus G Dalgleish

Front Immunol· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biovacc-19: A Candidate Vaccine for Covid-19 (SARS-CoV-2) Developed from Analysis of its General Method of Action for Infectivity.
Birger Sørensen, Andres Susrud, Angus George Dalgleish

QRB Discov· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mycobacterial immunotherapy for prostate cancer: where can we go from here?
Vasilis Stavrinides, Angus Dalgleish, John P Copier, Caroline M Moore

Nat Rev Urol· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma.
Jonathan S Cebon, Martin Gore, John F Thompson, Ian D Davis, Grant A McArthur, Angus G Dalgleish

J Immunother Cancer· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development and application of two novel monoclonal antibodies against overexpressed CD26 and integrin α3 in human pancreatic cancer.
Gustavo A Arias-Pinilla, Angus G Dalgleish, Satvinder Mudan, Izhar Bagwan, Anthony J Walker

Sci Rep· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Why do the majority of patients not respond at all, or only partially or transiently, to immunotherapy?
Angus G Dalgleish

Expert Rev Anticancer Ther· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term benefit from immune modulation and anti-inflammatory treatment in metastatic mesothelioma.
Angus G Dalgleish, Emma McLean, Nirav Patel, Najib Rahman

Respir Med Case Rep· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The successful treatment of metastatic androgen receptor-positive tumours of parotid origin with androgen receptor blockade and immunotherapy.
Angus G Dalgleish, Silvana Di Palma, Kannon Nathan, Barry Powell, Nirav Patel

Eur J Cancer· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serum Apolipoprotein E and Other Inflammatory Markers Can Identify Non-Responding Patients to a Dendritic Cell Vaccine.
Hayley Leeman, Elwira Kaminska, Deborah Green, Mark Bodman-Smith, Andrew Gravett, Angus G Dalgleish

Transl Oncol· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro culture with gemcitabine augments death receptor and NKG2D ligand expression on tumour cells.
Andrew M Gravett, Angus G Dalgleish, John Copier

Sci Rep· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Report of Objective Clinical Responses of Cancer Patients to Pharmaceutical-grade Synthetic Cannabidiol.
Julian Kenyon, Wai Liu, Angus Dalgleish

Anticancer Res· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The failure of radical treatments to cure cancer: can less deliver more?
Angus G Dalgleish, Peter L Stern

Ther Adv Vaccines Immunother· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis